Chronic Pelvic Floor Myalgia (Investigational Adjunct)
Investigational adjunct for chronic pelvic floor myalgia; pelvic-floor physical therapy is first-line; biofeedback, trigger-point injection, and (for selected refractory cases) onabotulinumtoxinA remain evidence-based.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Not FDA-cleared for chronic pelvic floor myalgia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational; intra-cavitary placement (rectum, vagina, urethra) is absolutely contraindicated.
- Какие доказательства существуют?
- Tier C (investigational). No controlled trials exist for hirudotherapy in pelvic floor myalgia. Evidence-based first-line management is specialized pelvic-floor physical therapy (internal and external myofascial release, biofeedback, relaxation training), with adjunctive trigger-point injection, and onabotulinumtoxinA for refractory cases. Multidisciplinary care across urology, gynecology, gastroenterology, pain medicine, and mental health is often needed.
- Основные риски
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness in the perineal or ischial region for 5 to 14 days
- Local skin infection or Aeromonas infection in a region adjacent to anus and genitals
- Allergic reaction to leech saliva
- Triggering or worsening of myofascial spasm if a bite site is too close to a trigger point
- Delay of evidence-based pelvic-floor physical therapy, biofeedback, or onabotulinumtoxinA
- Catastrophic risk if a practitioner attempts intra-rectal, intra-vaginal, or peri-urethral placement (absolute contraindication)
- Кому не следует это рассматривать
- Anyone offered intra-rectal, intra-vaginal, or urethral placement (this is absolutely contraindicated)
- Anyone with active pelvic infection (PID, prostatitis, abscess)
- Patients with inflammatory bowel disease and perianal involvement
- Patients within 12 weeks of pelvic or anorectal surgery
- Patients with anal fissure, fistula, or bleeding hemorrhoid
- Pregnant or lactating patients
- Patients who have not completed at least 12 weeks of specialized pelvic-floor PT
- О чём спросить врача
- Have I had a specialized pelvic-floor physical therapy program for at least 12 weeks?
- Has trigger-point injection or onabotulinumtoxinA been considered for refractory disease?
- Have my bowel, bladder, and sexual dysfunction symptoms been addressed in a multidisciplinary plan?
- Where exactly will the leech be placed — confirm it is external skin only?
- What is the practitioner's experience with this indication and Aeromonas-prevention plan?
- What is the realistic expected benefit given the absence of controlled trials?
- Когда срочно обратиться за медицинской помощью
- Severe pelvic, rectal, or genital pain that is new or sharply increased
- Fever above 38.0 C / 100.4 F or chills
- Visible bleeding from the rectum, vagina, or urethra
- Spreading redness, warmth, pus, or red streaks at any bite site
- Bleeding from a bite site lasting more than 24 hours
- Difficulty urinating or defecating, or new urinary retention
Что это НЕ означает
- It does not replace specialized pelvic-floor physical therapy, which has the strongest evidence.
- It does not address concurrent bowel, bladder, or sexual dysfunction that often accompany pelvic floor myalgia.
- Leeches are never placed inside the rectum, vagina, or urethra.
- Only anecdotal evidence exists.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- urogenital
- ICD-10
- N94.89, M62.838, K59.4
- Safety tier
- high
Evidence Summary
Chronic pelvic floor myalgia (hypertonic pelvic floor dysfunction, levator ani syndrome, coccygodynia variants) is myofascial dysfunction of the pelvic floor producing pelvic, perineal, or rectal pain, often with bowel, bladder, or sexual symptoms. Evidence-based first-line management is specialized pelvic-floor physical therapy (internal and external myofascial release, biofeedback, relaxation training), with adjunctive trigger-point injection, and onabotulinumtoxinA for refractory cases. Multidisciplinary care (urology, gynecology, gastroenterology, pain medicine, mental health) is often needed. No published controlled trials of hirudotherapy exist for pelvic floor myalgia. The perineum and ischiorectal region are uniquely high-risk for bleeding and infection; intra-rectal or vaginal application is absolutely contraindicated.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Intra-rectal, intra-vaginal, or urethral placement (absolute)
- Active pelvic infection (PID, prostatitis, abscess)
- Inflammatory bowel disease with perianal involvement
- Recent pelvic or anorectal surgery
- Anal fissure, fistula, or hemorrhoid with bleeding
- Pregnancy or lactation
Related Conditions
Peyronie's Disease (Stable Phase)
Investigational use for stable-phase Peyronie's disease; case-report-level evidence only. Standard treatments (verapamil, collagenase, surgery) remain first-line.
Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)
Investigational use for category III CP/CPPS; small case series suggest symptom reduction. Multimodal therapy remains standard.
Chronic Prostatitis / Chronic Pelvic Pain Syndrome (Extended Protocol)
Investigational extended-protocol adjunct for NIH Category III chronic prostatitis/CPPS; small case series only; UPOINT-directed therapy remains primary.
Interstitial Cystitis / Bladder Pain Syndrome (Investigational)
Highly investigational adjunct for IC/BPS refractory to conventional therapy; case reports only; AUA-guideline stepwise therapy remains primary.